×

Celldex ends eczema drug development after mid-stage trial failure

By Thomson Reuters Nov 19, 2026 | 3:36 PM

Nov 19 (Reuters) – Celldex Therapeutics said on Thursday it would stop developing its experimental drug for eczema after the ​treatment failed to meet the ‌main and key secondary goals of a mid-stage study.

Shares of the company were down over 3% in extended trading.

• The study enrolled 131 patients ‌with ​moderate-to-severe atopic dermatitis, a ⁠chronic inflammatory skin condition ⁠commonly known as eczema

• The drug, barzolvolimab, did not significantly reduce itching after 16 weeks and showed no meaningful ​improvement over placebo on other key measures

• The drug reduced mast cells, immune ⁠cells involved in allergic ⁠and inflammatory reactions, but the ​results suggest they are not the main driver ​of atopic dermatitis, the company said

• ‌Celldex said the limited improvements fell short of its threshold for further development, with no added benefit after 32 weeks

• The ⁠treatment was well tolerated, with a safety profile consistent with earlier studies

• Celldex will continue late-stage ⁠studies ‌of barzolvolimab in three hive-related ⁠skin conditions: chronic spontaneous urticaria, cold ​urticaria ‌and symptomatic dermographism

• The company ​plans to ⁠seek US approval for the drug in chronic spontaneous urticaria in 2027 and announce additional indications by year-end

(Reporting by Kunal Das in Bengaluru; Editing by Shinjini Ganguli and ​Perla Velasco)